Pharma companies directory 2026

Pharmaceutical Companies in Mexico

Mexico is the second-largest medicines market in Latin America, worth close to $20bn at retail value in 2024, and it is unusual in the region for the depth of its domestically owned manufacturers: Sanfer, Liomont, Silanes, PiSA and Genomma Lab sell far beyond the country and hold plants that supply public tenders at scale.

Approval of every product rests with COFEPRIS, whose registration backlog and reliance on reference-agency pathways shape launch timing more than commercial planning does. Public demand is fragmented across IMSS, ISSSTE, IMSS-Bienestar, PEMEX and state health services, but consolidated purchasing has swung between UNOPS, the Secretaría de Salud and, since 2024, Birmex as a state-run buyer and distributor, leaving suppliers with unpredictable award cycles and long receivables. Private demand runs through wholesalers such as Nadro and Marzam into more than 60,000 pharmacy outlets, where consultorios adjacent to pharmacies generate a large share of first-line prescriptions. This page profiles the manufacturers, affiliates and institutions a brand must understand before deciding how to compete for either the public or the private channel in Mexico.

Updated September 2026 · COFEPRIS — Registros Sanitarios de Medicamentos and licensed establishments database as of September 2026 · 20 named accounts

Request a proposal for Mexico Browse the 20 companies

$19.8bn

Mexican pharmaceutical market at retail value, 2024 (ANAFAM / IMARC)

~62,500

Establishments selling medicines, INEGI DENUE, May 2024

77.4m

IMSS beneficiaries (derechohabientes), December 2024

~18%

Public sector share of market value, 2025 (private channel holds the rest)

Named accounts

Top pharmaceutical companies in Mexico

Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against COFEPRIS — Registros Sanitarios de Medicamentos and licensed establishments database (as of 2026-09-03).

#	Company	HQ	Type	Therapeutic focus	Notes
01	COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)	Mexico City	Government	Registration, GMP certification, pharmacovigilance and pricing oversight	The federal regulator; its registration queue, reliance-pathway rulings and plant inspections determine when and whether a product can be sold in Mexico.
02	IMSS (Instituto Mexicano del Seguro Social)	Mexico City	Government	Social security health system covering formal-sector workers and families	Serving 77 million beneficiaries, IMSS is the largest single purchaser of medicines in the country and anchors the consolidated public tenders.
03	Birmex (Laboratorios de Biológicos y Reactivos de México)	Mexico City	Government	State purchasing agent, vaccine importer and public-sector logistics operator	Reassigned in 2024 to run consolidated purchases and distribution for federal health institutions, Birmex is now the counterpart for most public volume.
04	Genomma Lab Internacional	Mexico City	Local	OTC medicines, personal care and branded generics across Latin America	BMV-listed and heavily advertised, Genomma has built its own plant in the State of Mexico and exports to 18 countries from a Mexican base.
05	Laboratorios Sanfer	Mexico City	Local	Branded generics, ophthalmology, women’s health, gastroenterology and OTC	One of the largest privately held Mexican groups, Sanfer has acquired brands from multinationals and operates across Central and South America.
06	Laboratorios Liomont	Mexico City	Local	Respiratory, gastrointestinal, pain and paediatric prescription brands	Family-owned manufacturer with plants in Ocoyoacac; it prospered in the 2021 vaccine-fill campaign and remains a frequent public-tender supplier.
07	Laboratorios Silanes	Mexico City	Local	Diabetes, cardiometabolic brands and antivenoms (Instituto Bioclon)	Silanes combines a strong metformin franchise with the world’s largest antivenom business, exported to the United States and Africa.
08	Grupo Neolpharma	Mexico City	Local	Generics, APIs, biotech and contract manufacturing for public tenders	Owner of Psicofarma and Alpharma, Neolpharma is a high-volume supplier to IMSS and ISSSTE and one of few Mexican groups making its own APIs.
09	Probiomed	Mexico City	Local	Biosimilars and recombinant biologics for oncology, nephrology and rheumatology	Mexico’s first biosimilar developer, with a Tenancingo biotech plant; its products compete with originators in institutional tenders.
10	Grupo PiSA Farmacéutica	Guadalajara	Local	Injectables, IV solutions, oncology, dialysis and hospital supplies	The dominant supplier of parenteral solutions and hospital injectables to public institutions, PiSA operates one of the largest plant networks in Latin America.
11	Landsteiner Scientific	Mexico City	Local	Generics, biosimilars and specialty hospital products	A mid-sized producer in Toluca that wins consolidated tender lots in oncology and anti-infectives and pursues biosimilar partnerships.
12	Laboratorios Chinoin	Mexico City	Local	Prescription brands in pain, respiratory and gastroenterology; OTC lines	Founded in 1936, Chinoin remains privately owned and pairs a doctor-detailing model with a well-known consumer franchise.
13	Laboratorios Senosiain	Mexico City	Local	Cardiovascular, metabolic and CNS branded generics	Senosiain’s Guanajuato plant supplies its own brands and licensed molecules, with a prescriber base built through long-standing cardiology detailing.
14	Laboratorios Sophia	Guadalajara	Local	Ophthalmology, from dry-eye drops to glaucoma and anti-infectives	The country’s reference ophthalmic manufacturer, Sophia exports across Latin America, supplies public eye-care programmes and detail ophthalmologists in every major city.
15	Laboratorios Carnot	Mexico City	Local	Gynaecology, urology, dermatology and metabolic prescription brands	A prescription-led Mexican house with an Argentine and Andean footprint, Carnot competes in specialist categories rather than commodity generics.
16	Pfizer México	Mexico City	MNC	Vaccines, oncology, anti-infectives, inflammation and hospital products	Pfizer’s Toluca plant is a regional supply hub, and its vaccine and biologic lines are among the highest-value lots in public tenders.
17	Sanofi México	Mexico City	MNC	Insulins, vaccines, rare disease, consumer health and established products	Runs an Ocoyoacac manufacturing site and supplies insulin and vaccines to IMSS and the national immunisation programme in volume.
18	Bayer de México	Mexico City	MNC	Cardiovascular, women’s health, ophthalmology and consumer health	Bayer manufactures in Lerma and Orizaba and leads several OTC categories through the pharmacy chains alongside its prescription business.
19	Grupo Nadro	Mexico City	Distributor	National pharmaceutical wholesale to chains, independents and hospitals	The largest private wholesaler in the country, Nadro is the route to independent pharmacies and a required listing for any retail launch.
20	Marzam	Mexico City	Distributor	Full-line wholesale, specialty logistics and pharmacy services	A second national wholesaler with cold-chain capacity and a growing specialty arm, Marzam also serves private hospitals and government contracts.

Primary research

These are the pharmaceutical companies accounts we study in Mexico

Need account-level or SKU-level data for a brand in Mexico? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

Planning research in Mexico?

Primary research, market access & HEOR. Proposals within 48 hours.

Top healthcare market research companies in Mexico (2026)

How the market is structured

How medicines reach patients in Mexico

Every marketed medicine needs a COFEPRIS registro sanitario, renewable every five years, and since 2020 the agency has accepted abbreviated reviews for products already cleared by the FDA, EMA, Health Canada, Swissmedic or the TGA, which is why most multinational launches now arrive within two to three years of a US approval. Once registered, a product is sold into two very different worlds. The public system buys through consolidated annual purchases that have changed hands repeatedly: the IMSS ran them until 2019, UNOPS was contracted for 2021–2022, the Secretaría de Salud and IMSS took them back, and from 2024 Birmex was designated the single purchaser and logistics operator for federal institutions, with mixed early results on delivery and payment. Awards are based on the Compendio Nacional de Insumos para la Salud, so a molecule outside the compendium cannot be bought by IMSS or ISSSTE at any price. The private channel is larger by value: manufacturers sell to national wholesalers such as Nadro, Marzam and Fármacos Nacionales, which supply the big chains Farmacias Guadalajara, Farmacias del Ahorro, Farmacias Benavides, Farmacias Similares and Walmart, as well as tens of thousands of independent pharmacies. Consultorios adyacentes a farmacias employ physicians who write a very large share of primary-care prescriptions, often for the chain’s own generics. Private hospitals buy directly from manufacturers or through specialised distributors, and out-of-pocket spending on medicines by households has more than doubled in real terms since 2018.

Local

Mexican-owned manufacturers, several with exports across Latin America, that dominate branded generics, hospital injectables and OTC and supply the bulk of consolidated public tender volume.

Genomma Lab Internacional
Laboratorios Sanfer
Laboratorios Liomont
Laboratorios Silanes
Grupo Neolpharma
Probiomed
Grupo PiSA Farmacéutica
Landsteiner Scientific
Laboratorios Chinoin
Laboratorios Senosiain
Laboratorios Sophia
Laboratorios Carnot

Multinational

Global companies with Mexican plants or large affiliates, carrying vaccines, biologics and innovative specialty brands into IMSS tenders and private hospitals.

Pfizer México
Sanofi México
Bayer de México

Regional

Latin American groups from Argentina, Brazil and Colombia that operate Mexican subsidiaries for branded generics and consumer health, usually via licensed local manufacturing.

Distributors & importers

National wholesalers, the state purchasing agent and the public institutions whose award decisions and payment terms define the commercial reality of the Mexican market.

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
IMSS (Instituto Mexicano del Seguro Social)
Birmex (Laboratorios de Biológicos y Reactivos de México)
Grupo Nadro
Marzam

What is moving

What is moving the pharmaceutical market in Mexico

Restructuring of consolidated public procurement

The move to Birmex as purchaser and logistics operator, combined with multi-year framework awards, is reshaping which manufacturers hold public volume and how quickly they are paid, creating openings for suppliers able to guarantee delivery.

Chronic disease burden and biosimilar entry

Mexico has one of the highest diabetes and obesity prevalences in the OECD, and the arrival of insulin, GLP-1 and oncology biosimilars from Probiomed, Landsteiner and importers is expanding institutional access while pressuring originator pricing.

Pharmacy chains and adjacent consultorios

Farmacias Similares, Guadalajara, del Ahorro and Benavides keep adding outlets and clinics, so pharmacy-based physicians increasingly determine first-line therapy and private-label generics gain share at the expense of branded prescriptions.

Nearshoring and export manufacturing

USMCA rules and announced investments of about MX$12bn in new capacity are attracting API, sterile and biologics production, strengthening Mexico as a supply hub for North and Latin America and raising GMP standards across the domestic industry.

BioNixus fieldwork

How BioNixus studies pharmaceutical companies in Mexico

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Mexico:

Consolidated tender landscaping by molecule across IMSS, ISSSTE and Birmex cycles since 2021: bidders, awarded prices, local versus imported share and reported delivery failures.
Consultorio-physician prescribing studies in Farmacias Similares, del Ahorro and Guadalajara clinics measuring brand versus private-label choice in primary-care categories.
Private hospital purchasing interviews at Grupo Ángeles, Christus Muguerza, ABC and Médica Sur covering formulary entry, distributor terms, payment cycles and willingness to switch to biosimilars.
Retail purchase-record audits at independent pharmacies in Mexico City, Guadalajara and Monterrey estimating wholesaler share and brand penetration for OTC and chronic-care baskets.

Questions

Frequently Asked Questions

Which pharmaceutical companies are the largest in Mexico by domestic sales?

Multinationals such as Pfizer, Sanofi, Bayer, Roche and Novartis lead in value, while Mexican groups Sanfer, Genomma Lab, PiSA, Liomont, Silanes and Neolpharma lead in units and hold most of the consolidated public tender volume. Exact ranks shift with tender cycles and peso movements, and audited retail data understate manufacturers whose sales are concentrated in institutional channels.

How long does COFEPRIS registration take for a new medicine?

Statutory timelines are 60 to 180 working days, but real durations depend on whether the product qualifies for the reliance pathway based on FDA, EMA or other reference approvals. Innovative products under reliance often clear within a year; complex generics and biosimilars usually take longer.

Who buys medicines for the Mexican public sector?

IMSS, ISSSTE, IMSS-Bienestar, PEMEX and state services are the end users, but purchasing has been centralised: Birmex has run the consolidated purchase and distribution since 2024, following earlier arrangements with UNOPS and the Secretaría de Salud. Inclusion in the Compendio Nacional is a precondition.

Why do pharmacy consultorios matter to pharmaceutical brands?

Physicians working in consultorios next to pharmacies see a very large share of primary-care visits and tend to prescribe what the adjoining pharmacy stocks, including private-label generics. Detailing them differs from targeting hospital specialists and often demands trade rather than medical marketing, since the chain’s procurement team decides what the consultorio can recommend.

How does BioNixus research pharmaceutical companies in Mexico?

BioNixus interviews IMSS and ISSSTE pharmacy chiefs, private hospital purchasers, chain category managers and consultorio physicians; maps consolidated tender awards by molecule; audits purchase records at independent pharmacies in Mexico City, Guadalajara and Monterrey; and profiles domestic manufacturers’ plant capacity and export footprints.

Is this list a ranking of Mexican pharmaceutical companies?

It is not. Companies appear because they shape either the public tender channel or the private pharmacy channel and because they surface repeatedly in COFEPRIS records, BMV filings and BioNixus fieldwork. Sequence carries no meaning about revenue or market share.

Sources

Data sources & methodology

This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Mexico. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

Primary register: COFEPRIS — Registros Sanitarios de Medicamentos and licensed establishments database, consulted 2026-09-03. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Mexico, not size.

ANAFAM submission on Mexican market size and IMSS prescription shortfalls; IMARC market estimate, 2024–2025
INEGI DENUE count of pharmaceutical retail establishments, May 2024; IMSS Informe al Ejecutivo on beneficiaries, December 2024
Bolsa Mexicana de Valores filings for Genomma Lab; Compendio Nacional de Insumos para la Salud and Birmex consolidated purchase notices, 2024–2026
BioNixus Mexico public-tender, hospital pharmacy and retail channel fieldwork, 2023–2026

BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

48-hour proposal

Need brand and competitor data in Mexico?

Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

Planning research in Mexico?

Primary research, market access & HEOR. Proposals within 48 hours.

Pharmaceutical Companies in Mexico

Top pharmaceutical companies in Mexico

These are the pharmaceutical companies accounts we study in Mexico

Planning research in Mexico?

How medicines reach patients in Mexico

Local

Multinational

Regional

Distributors & importers

What is moving the pharmaceutical market in Mexico

Restructuring of consolidated public procurement

Chronic disease burden and biosimilar entry

Pharmacy chains and adjacent consultorios

Nearshoring and export manufacturing

How BioNixus studies pharmaceutical companies in Mexico

Related research and directories

Frequently Asked Questions

Data sources & methodology

Need brand and competitor data in Mexico?

Planning research in Mexico?